Suppr超能文献

皮下注射阿扑吗啡起始治疗与晚期帕金森病患者冲动控制障碍减轻相关:来自法国NS-Park队列的见解

Subcutaneous Apomorphine Infusion Initiation Is Associated with Impulse Control Disorder Attenuation in Advanced Parkinson's Disease Patients: Insights from the French NS-Park Cohort.

作者信息

Desjardins Clément, Bastos Paulo André Dias, Lanore Aymeric, Brefel-Courbon Christine, Benatru Isabelle, Giordana Caroline, de Maindreville Anne Doe, Castelnovo Giovanni, Remy Philippe, Defebvre Luc, Thiriez Claire, Prange Stéphane, Houeto Jean-Luc, Foubert Alexandra Samier, Ory-Magne Fabienne, Barbosa Raquel Pinhero, Bertille Nathalie, Corvol Jean-Christophe, Rascol Olivier, Fabbri Margherita

机构信息

Department of Neurology, Rothschild Foundation Hospital, Paris, France.

Department of Clinical Pharmacology and Neurosciences, Toulouse Parkinson Expert Centre, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), French NS-Park/F-CRIN Network, University of Toulouse 3, CHU of Toulouse, INSERM, Toulouse, France.

出版信息

Mov Disord Clin Pract. 2025 Jul 17. doi: 10.1002/mdc3.70240.

Abstract

BACKGROUND

Impulse control disorders (ICD) are common non-motor complications in Parkinson's disease (PD), particularly in patients receiving oral dopamine agonists (DA). Continuous subcutaneous apomorphine infusion (CSAI) is a device-aided therapy for advanced PD, but its effects on ICD remain underexplored in real-world settings.

OBJECTIVES

To assess the impact of CSAI initiation on ICD prevalence and severity in a large real-world PD cohort and to compare ICD evolution in CSAI-treated patients versus orally-treated controls.

METHODS

We analyzed data from the national prospective observational NS-Park cohort, selecting patients with documented ICD status before and after CSAI initiation. Changes in ICD prevalence and severity based on the MDS-UPDRS sub-item 1.6 were assessed using paired statistical tests, with additional sensitivity analyses based on time-restricted sub-cohorts (considering 60-, 24- and 12-months follow-up). A matched case-control analysis and a propensity score matching were used to compare CSAI-treated patients to orally-treated PD patients.

RESULTS

149 patients were included in the analysis. Before CSAI initiation, slight and mild/severe ICDs were present in 17% and 5% of the patients, respectively. After CSAI starting, ICD prevalence significantly decreased from 22% to 13%, (P = 0.003). These improvements were consistent across different time windows, despite an overall increase in DA levodopa-equivalent dose, with no associated mood worsening (up to 24-month follow-up). CSAI was associated with longitudinal ICD reduction, contrasting with the stable or worsening ICD trajectory in orally-treated controls, though trajectories were not statistically different.

CONCLUSIONS

The presented findings of our real-life cohort suggest that ICD tend to improve following CSAI initiation in patients with PD, likely due to a reduction of oral DA or the effect of continuous dopaminergic stimulation provided by the pump. While this observation is clinically relevant, it should be interpreted with caution given the study's observational design and the limitations inherent to using MDS-UPDRS sub-items for ICD assessment.

摘要

背景

冲动控制障碍(ICD)是帕金森病(PD)常见的非运动并发症,尤其是在接受口服多巴胺激动剂(DA)的患者中。持续皮下注射阿扑吗啡(CSAI)是一种用于晚期PD的器械辅助治疗方法,但在实际临床环境中,其对ICD的影响仍未得到充分研究。

目的

评估在一个大型的真实世界PD队列中开始CSAI治疗对ICD患病率和严重程度的影响,并比较接受CSAI治疗的患者与口服药物治疗的对照患者中ICD的演变情况。

方法

我们分析了来自全国前瞻性观察性NS-Park队列的数据,选择了在开始CSAI治疗前后有ICD记录的患者。使用配对统计检验评估基于MDS-UPDRS子项1.6的ICD患病率和严重程度的变化,并基于时间限制的子队列进行额外的敏感性分析(考虑60个月、24个月和12个月的随访)。采用匹配病例对照分析和倾向评分匹配方法,将接受CSAI治疗的患者与接受口服药物治疗的PD患者进行比较。

结果

149名患者纳入分析。在开始CSAI治疗前,分别有17%和5%的患者存在轻度和中度/重度ICD。开始CSAI治疗后,ICD患病率从22%显著降至13%(P = 0.003)。尽管左旋多巴等效剂量总体增加,但在不同时间窗内这些改善均一致,且无相关情绪恶化(随访至24个月)。CSAI与ICD的纵向减少相关,这与口服药物治疗的对照患者中ICD轨迹稳定或恶化形成对比,尽管轨迹在统计学上无差异。

结论

我们真实队列的研究结果表明,PD患者开始CSAI治疗后ICD往往会改善,这可能是由于口服DA减少或泵提供的持续多巴胺能刺激的作用。虽然这一观察结果具有临床相关性,但鉴于该研究的观察性设计以及使用MDS-UPDRS子项评估ICD的固有局限性,应谨慎解读。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验